Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel
Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction. Treatment is unclear for sarcoidosis patients who develop autoimmun...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007115300526 |
id |
doaj-c6bf877633f148daba534a488175926c |
---|---|
record_format |
Article |
spelling |
doaj-c6bf877633f148daba534a488175926c2020-11-24T23:09:58ZengElsevierRespiratory Medicine Case Reports2213-00712016-01-0117C5710.1016/j.rmcr.2015.11.001Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gelYing Zhou0Elyse E. Lower1Huiping Li2Robert P. Baughman3Department of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes, Eden Ave, Cincinnati, OH, 45267, USADepartment of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes, Eden Ave, Cincinnati, OH, 45267, USADepartment of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, ChinaDepartment of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes, Eden Ave, Cincinnati, OH, 45267, USAInfliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction. Treatment is unclear for sarcoidosis patients who develop autoimmune reactions to infliximab. We report a case of a patient with advanced sarcoidosis who developed a myositis type reaction to infliximab characterized by diffuse muscle achiness and weakness and marked elevations in serum creatinine phosphokinase (CPK) and aldolase. Manifestations of sarcoidosis and myositis improved after Acthar treatment. This is the first report of successful treatment with Acthar in a patient with advanced sarcoidosis with an autoimmune reaction to infliximab.http://www.sciencedirect.com/science/article/pii/S2213007115300526SarcoidosisMyositisInfliximabActhar |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ying Zhou Elyse E. Lower Huiping Li Robert P. Baughman |
spellingShingle |
Ying Zhou Elyse E. Lower Huiping Li Robert P. Baughman Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel Respiratory Medicine Case Reports Sarcoidosis Myositis Infliximab Acthar |
author_facet |
Ying Zhou Elyse E. Lower Huiping Li Robert P. Baughman |
author_sort |
Ying Zhou |
title |
Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel |
title_short |
Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel |
title_full |
Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel |
title_fullStr |
Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel |
title_full_unstemmed |
Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel |
title_sort |
sarcoidosis patient with lupus pernio and infliximab-induced myositis: response to acthar gel |
publisher |
Elsevier |
series |
Respiratory Medicine Case Reports |
issn |
2213-0071 |
publishDate |
2016-01-01 |
description |
Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction. Treatment is unclear for sarcoidosis patients who develop autoimmune reactions to infliximab. We report a case of a patient with advanced sarcoidosis who developed a myositis type reaction to infliximab characterized by diffuse muscle achiness and weakness and marked elevations in serum creatinine phosphokinase (CPK) and aldolase. Manifestations of sarcoidosis and myositis improved after Acthar treatment. This is the first report of successful treatment with Acthar in a patient with advanced sarcoidosis with an autoimmune reaction to infliximab. |
topic |
Sarcoidosis Myositis Infliximab Acthar |
url |
http://www.sciencedirect.com/science/article/pii/S2213007115300526 |
work_keys_str_mv |
AT yingzhou sarcoidosispatientwithlupuspernioandinfliximabinducedmyositisresponsetoacthargel AT elyseelower sarcoidosispatientwithlupuspernioandinfliximabinducedmyositisresponsetoacthargel AT huipingli sarcoidosispatientwithlupuspernioandinfliximabinducedmyositisresponsetoacthargel AT robertpbaughman sarcoidosispatientwithlupuspernioandinfliximabinducedmyositisresponsetoacthargel |
_version_ |
1725608842094444544 |